EAU: 90-Day Mortality Rate 9.2 Percent for Emergency Hematuria
Medically reviewed by Drugs.com
via HealthDayTUESDAY, March 17, 2026 -- Ninety-day mortality is 9.2 percent for people presenting with emergency hematuria, with malignancy the underlying cause for 25 percent, according to a study presented at the European Association of Urology Congress, held March 13 to 16 in London.
Nikita R. Bhatt, M.B.B.S., from St. Vincent's University Hospital in Dublin, and colleagues describe current management practices and clinical outcomes in patients presenting with emergency hematuria in an international, multicenter, prospective observational study. Data were obtained for 8,500 patients from 382 centers over one year.
The median length of stay was four days, and 90-day mortality and readmission rates were 9.2 and 31 percent, respectively. The researchers found that on admission, 5, 5, 11, and 21 percent were hemodynamically unstable, septic, required high-dependency care, and required blood transfusion, respectively. In 35 percent of cases, ward-based management was successful. During admission, 47 percent did not undergo imaging and only 35 percent underwent intervention. Overall, the underlying cause was malignancy in 25 percent (12.5 percent preexisting; 12.5 percent newly diagnosed); a further 5 percent of patients were diagnosed during follow-up. Urothelial carcinoma accounted for 20 percent and a further 4 percent of malignancies during admission and follow-up, respectively. The median time to diagnosis was one day and 21 days during admission and follow-up, respectively.
"Our findings show how important it is that doctors take the necessary steps to identify the cause of the problem," Bhatt said in a statement. "For patients, the message is clear: if you have visible blood in your urine, don't ignore it. See your doctor as soon as you can."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-18 08:54
Read more
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann Pick Disease Type C
- Aggression in Adolescence Predicts Advanced Biologic Aging by Age 30 Years
- FDA Approves Hernexeos, the First Targeted Therapy for Adults with HER2-Mutant Advanced NSCLC as an Initial Treatment Option
- Many Seniors Gain Physical, Mental Fitness As They Age, Study Finds
- Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions